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Abstract 
The genomic revolution has transformed our understanding of urinary tract infection (UTI). There 
has been a paradigm shift from the dogmatic statement that urine is sterile in healthy people, as 
we are becoming forever more familiar with the knowledge that bacterial communities exist within 
the urinary tracts of healthy people. 
Metagenomics can investigate broad populations of microbial communities, analyzing all the DNA 
present within a sample, providing comprehensive data regarding the state of the 
microenvironment of a patient’s urinary tract. This permits medical practitioners to more accurately 
target organisms that may be responsible for disease – a form of ‘precision medicine’. 
This paper explores the limitations of traditional methods of culture and sensitivity and delves into 
the recent studies involving new high-throughput genomic technologies in urological research, 
demonstrating the advances made in the role of urinary microbiome in a whole spectrum of 
pathologies from urinary tract infection, to prostate cancer. Finally, we discuss the challenges that 
must be overcome for such technology to become widely used in clinical practice. 
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Introduction 
The genomic revolution has transformed our understanding of urinary tract infection (UTI). There 
has been a paradigm shift from the dogmatic statement that urine is sterile in healthy people, as 
we are becoming forever more familiar with the knowledge that bacterial communities exist within 
the urinary tracts of healthy people. The term ‘microbiota’ refers to the microorganisms that exist 
within a niche such as the kidney, bladder, prostate etc. [1]. ‘Microbiome’, instead, refers to the 
collective microbial community occupying a reasonable well-defined habitat with its distinct physic-
chemical properties within their theater of activity e.g. in urine, as a result of interaction of different 
microbiotas. The role of these complex microbial communities is now known to be of significant 
importance in the pathophysiology of infection and is currently a hot topic of basic science and 
clinical research [1]. However, their function has not been quite so extensively studied within the 
realm of urological medicine. 
Metagenomics allows for large quantities of DNA strands to be analyzed simultaneously, providing 
a wealth of information about the presence of large numbers of species in a timely fashion. One of 
the most attractive features of this technology to clinicians is its ability to provide much more 
comprehensive data regarding the state of the microenvironment of a patient’s urinary tract than is 
yielded by a traditional culture and sensitivity (C&S), permitting medical practitioners to more 
accurately target organisms that may be responsible for disease – a form of ‘precision medicine’. 
This paper seeks to evaluate the recent studies conducted within the urinary microbiome and 
different microbiotas within the urogenital system that have demonstrated the utility of the new 
high-throughput genomics in clinical practice, and how advances in the understanding of the role of 
microbiome have been made as a result of this technology. 
Current high-throughput genomics technologies 
Over the last two decades, the rapid development of high-throughput molecular methods to detect 
and characterize the enormous amount of existing bacterial, fungal, and viral pathogens within the 
human body enabled identification of a variety of different taxa per sample in order to diagnose the 
most dangerous and life-threatening “superbugs”. Regarding their technical aspects, high-
throughput identification methods can be classified as PCR-based quantification methods, 
hybridization-based methods (e.g. microarrays), second-generation fingerprinting methods e.g. 
RAD- seq) and sequence-based methods, e.g. metabarcoding, (meta)transcriptomics and 
(meta)genomics. 
Also known as ‘shotgun sequencing’, metagenomic sequencing (MGS) can investigate the broad 
populations of microbial communities from complex environmental or clinical samples that helps in 
the discovery of novel organisms and can exemplify the dynamics of a population under different 
conditions [2]. All DNA present in a sample is sequenced before bioinformatic analyses are used to 
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filter out the DNA that is human or from a known non-pathogenic organism in order to identify the 
causative agent. Usually, MGS is used to sequence the whole genome; it is a sensitive method but 
can produce redundant findings due to the detection of normal inhabitants of the human 
microbiome, rendering it difficult to interpret [3]. Next Generation Sequencing (NGS) as a branch of 
MGS is a more elaborate term that collectively refers to high-throughput DNA sequencing 
strategies that can produce robust and large amounts of genomic data in a single reaction. 
Additional methodologies include gene expression profiling by RNA sequencing (transcriptomics), 
mapping of DNA binding proteins and chromatin analysis, epigenetics, discovery of noncoding 
RNAs, exome sequencing, single nucleotide polymorphism detection, and amplicon resequencing 
[3]. NGS, also called ‘massively parallel sequencing’, works at a lower cost per base than the ‘first 
generation Sanger sequencing’; these methods encompass ‘second- ‘and ‘third-generation 
sequencing’. Therefore, NGS is a more commonly used term in literature, with its clinical utility 
discussed further in this paper. The most commonly used NGS platforms are illustrated in Figure 1 
[4]. 
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Figure 1. Scheme of step-wise approach of most commonly used NGS platforms. The primary 
molecules from sample are converted into double-stranded DNA which is then ligated by adapters. 
Adapters allow the binding of the library molecules to surfaces for subsequent amplification with 
separation prior to sequencing. An advanced Illumina sequencing platform uses four differently 
labelled nucleotides during sequencing process in multiple cycles with the desired read of length. 
Reprinted from “Analysis of plant microbe interactions in the era of next generation sequencing 
technologies,” by Claudia Knief, 2014, Frontiers in Plant Science, 5, p. 216. Copyright 2014 Knief. 
The 16S rRNA gene is highly conserved and found in all bacterial genomes. The specific 
sequences of this region are unique to each individual bacterial species. Over the last few years, a 
combination of PCR amplification and sequence analysis of this gene became the accepted 
reference standard for detection of unknown bacterial species for a single isolate, e.g. in urine 
sample [5,6]. This standard marker is a semi-quantitative assay which reports the total bacterial 
load as low, medium or high that corresponds to ranges for standard C&S colony forming units 
(CFU) in agar plate as <105, 106 -107, and >107 per ml, respectively.  
NGS can identify multiple species from a polymicrobial infection found in numerous patient 
specimens. NGS does not require growth, so it can identify gram-negative, gram-positive, and 
anaerobic bacteria as well as fungi/yeast/molds all in the same specimen using one extraction 
method. NGS can not only detect the bacterial species, but also delivers information about 
genotypic antibiotic resistance, which may be used to predict phenotypic resistance. Clinical 
guidance regarding antimicrobial resistance may then be provided. Genetic profiling is intended to 
facilitate timely management; a contrast to the 2-5-day turnaround time of C&S [3]. Sequencing 
directly any clinical samples would allow NGS analysis to be conducted within one working day, 
even within a matter of hours depending on the specific platform that is utilized. For example, using 
Illumina platform, the data analysis time varies based on the number of sequence reads per 
sample, but the average time taken is 5 minutes per sample. Performing data analysis on the 
entire run takes approximately 6 hours.  
While the amplification step is relatively fast, the analytic process is still time consuming. The set of 
data recovered is going through a bioinformatics pipeline prior to analysis. The bioinformatics 
pipeline takes the raw sequence data and performs cleaning, i.e. denoising. During denoising, the 
sequences are checked for chimeras and singletons; these sequences are removed. In addition, 
denoising will remove any sequences that have errors in the barcode, that don’t meet at least half 
of the intended fragment length, and that are below our quality threshold for error rates. These 
sequences are deemed too low quality to provide accurate information in the target gene region. 
All of the high-quality sequences are then analyzed through the curated database to match against 
all microbes, including pathogens, normal flora, and opportunistic pathogens. 
In general, NGS is currently still in its infantile stage, where phenotypic susceptibility data is 
extracted from a reference library of more than 25,000 specimens. It is possible, however, for 
clinical phenotype to be at least partially independent of genetic determinants, such as in the case 
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of ‘intrinsically resistant microorganisms’, or frequently mutating genes [3]. Therefore, at this stage, 
the genotypic characteristics do not always elucidate phenotypic features with ideal concordance 
for the choice of treatment, especially in ‘superbugs’ such as multi-drug resistant Escherichia coli 
or Pseudomonas aeruginosa.  
Other available technology that could possibly compete with NGS in terms of fast microbial 
detection and identification is single-and-multiplex polymerase chain reaction (PCR) combined with 
extended or enhanced quantitative urine culture techniques. Although multiplex PCR assays have 
the advantage of a rapid turnaround time (between one hour to one day) compared to NGS, 
specific primers are needed to amplify sequences and so their design must perpetually be updated 
so as to detect new variants [7]. Therefore, even a small error in the choice of primers can largely 
hinder antibiotic stewardship. 
The following clinical case demonstrates the comparative value of standard C&S versus PCR-
based and extended C&S (MicroGenDX PCR and MD Labs) versus NGS technologies (Volente, 
MicroGenDX DNA) (Table 1). This case reflects the complexity of standardization and interpretation 
of the results of different techniques that can dramatically affect antibiotic stewardship in the 
treatment of UTI. This clinical case demonstrates the superiority of NGS-based techniques over 
standard C&S in that the NGS-based techniques provided a broader pathogen profile and 
respective pathogen load. This case also illustrates the challenges that come from heterogeneity of 
antibiotic resistance gene reporting by different NGS platforms. This serves to prove the 
substantial clinical utility and diagnostic potential that the NGS-based techniques harbor, but also 
highlights the necessity for standardization of the analysis and reporting of antibiograms and 
antibiotic resistance data. It is possible that NGS will change the way chronic infections are 
managed as the standard approaches were not comprehensive enough to isolate and identify a 
lingering infection. This case demonstrates how NGS provided a diagnostic breakthrough for the 
patient in question, who was suffering with recurrent UTI, something that standard diagnostic 
approaches had failed to achieve in the past. 
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Table 1. Clinical case synopsis with comparison of laboratory results. 
Clinical history 
An 82-year-old lady with a history of recurrent UTI (more than three episodes of UTI per year) presented to the clinic 
with an acute episode after first intra-detrusor injection of Botox for her urge incontinence. She complained of dysuria, 
daytime frequency (10-12 times per day), nocturia (4-5 times per night), suprapubic pain, chills, rigors, and was 
marginally febrile. A mid-stream urine catch sample was obtained and sent for standard urinalysis, C&S, MD laboratory 
for singleplex PCR for pathogen detection with extended C&S, Volente Laboratories using multiplex PCR for both 
bacterial and fungal detection and susceptibility, and MicroGenDx using PCR for susceptibility and NGS for 
quantitative pathogen detection. Urinalysis revealed a large presence of leukocyte esterase, positive nitrites, and a 
small amount of red blood cells. Empiric treatment was initiated with Trimethoprim/Sulfamethoxazole 400/160mg twice 
per day. The results from all techniques were back within 5 days. There was a high concordance between C&S and 
PCR-based techniques to detect a high load of E. coli (>105 per ml) while MD labs and Volente were able to identify 
an additional mixed skin flora and coagulase negative Staphylococcus species. However, NGS detected a dominant 
pathogen as Bacteroides fragilis (50%) while E. coli was the second dominant species (48%). In terms of susceptibility, 
the standard C&S, MD labs and NGS revealed multi-drug resistance, including to fluoroquinolone and beta-lactam 
antibiotics. Primers used by Volente did not detect a quinolone resistant gene, and therefore the company 
recommended the use of fluoroquinolones as a treatment option. Based on the presence of quinolone resistant genes 
detected by NGS, a targeted antimicrobial therapy was administered using Clindamycin 300mg twice per day and 
Vancomycin 125mg q 6hrs for a total of 14 days, and alternative medications (probiotics, cranberry extract and D-
mannose). By the fifth day, the patient’s symptoms subsided, and upon follow-up, on day 14, she denied all symptoms. 
The control urine DNA sequence results demonstrated a low load of E. coli while all other techniques demonstrated 
an undetectable level of E. coli and other baseline pathogens. 
Laboratory tests 
Test Microbes detected Antibiotic resistance detected Antibiotic resistance not detected 
Culture and 
sensitivity 
Escherichia coli 
(ESBL) 
Ampicillin  
Ampicillin/Sulbactam 
Cefazolin  
Cefepime 
Ceftazidime 
Ceftriaxone 
Cefuroxime 
Ciprofloxacin  
Levofloxacin 
Tetracycline  
Trimethoprim/Sulfamethoxazole 
Amikacin 
Amoxicillin/ Clavulanate 
Ertapenem 
Gentamicin 
Imipenem 
Meropenem  
Nitrofurantoin 
Piperacillin/Tazocin 
Tobramycin 
 
 
MD Labs Escherichia coli 
(ESBL) 
Amoxicillin/Clavulanate 
Ampicillin 
Cefazolin 
Cefepime 
Ceftriaxone 
Ciprofloxacin 
Levofloxacin 
Tetracycline 
Trimethoprim/Sulfamethoxazole 
Ertapenem 
Gentamycin 
Nitrofurantoin 
Piperacillin/Tazobactam 
 
Volente Escherichia coli Class A beta-lactamases (CTX-
M1, M2, M9, M8/25 groups) 
Macrolide 
Lincosamide 
Streptogramin 
Tetracycline  
Trimethoprim/Sulfamethoxazole 
AmpC beta-lactamases 
Class A beta-lactamases (SHV, KPC groups) 
Class B metallo-beta-lactamases 
Class D oxacillinases 
Fluoroquinolone 
Methicillin 
Minor extended spectrum beta-lactamases 
Vancomycin 
Staphylococcus 
(coagulase 
negative: 
epidermidis, 
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haemolyticus, 
lugdunensis, 
saprophyticus) 
MicroGenDX 
PCR 
Escherichia coli Aminoglycoside 
Beta-lactam (except 
carbapenem) 
Methicillin  
Quinolone 
Carbapenem 
Macrolide 
Tetracycline 
Vancomycin 
Prevotella bivia 
Enterococcus 
faecalis 
MicroGenDX 
DNA 
sequence 
Bacteroides 
fragilis (50%) 
 Recommended antibiotics from library: 
- B. fragilis: 
o Doripenem 
o Clindamycin 
o Tetracycline 
- E. coli: 
o Trimethoprim/Sulfamethoxazole 
o Nitrofurantoin 
o Vancomycin 
o Linezolid 
Escherichia coli 
(48%) 
 
*Bolded text reflects differences of susceptibility or resistance to certain antibiotics between 
different techniques. 
Clinical application of NGS in urological medicine 
A limited number of trials have been found in the current body of literature regarding urinary tract 
microbiome.  
Urinary Tract Infection 
In a phase II study by McDonald et al. examining the diagnosis and treatment of acute 
uncomplicated and complicated cystitis, symptom scores were significantly better for those patients 
whose treatment was based on NGS results as opposed to traditional C&S [8]. All 44 patients 
showed positive results in DNA sequencing tests, while only 13/44 patients had positive urine 
culture tests. In patients who showed negative culture results, but positive NGS results, symptoms 
improved when they started treatment based on the results of NGS. Although this study was of a 
small size, it shows that NGS may be of great use, particularly in patients who continue to 
experience symptoms after typical empirical antibiotic therapy. Furthermore, anaerobic bacteria 
were detected in 20 of 44 patients via NGS – culpable for UTI symptoms in 10 of these patients. 
This appears to be yet another benefit of NGS, as anaerobic bacteria have classically been missed 
in cases of UTI due to the difficulty in detecting them via culture methods. 
Wagenlehner et al demonstrated that 141/588 patients (24%) with typical symptoms of acute lower 
uncomplicated UTI and pyuria had negative urine cultures i.e. <103 CFU/mL, furthering our 
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understanding of the limitations of urine cultures in their ability to detect clinically important 
infections [9]. 
Prophylaxis of UTI following transrectal biopsy 
Elshal et al compared the post-transrectal biopsy infectious complication (TBIC) rate between 
patients separated into standard (3 days 500mg ciprofloxacin twice daily, beginning the night 
before the biopsy), augmented (ciprofloxacin and single 160mg gentamicin IM), and targeted 
prophylaxis (based on results of rectal swab cultures). There was a lower rate of TBICs among the 
patients allocated to the augmented prophylaxis group, regardless of the variation in the number of 
biopsy cores taken when compared to the other two groups [10]. 
Mouraviev et al. evaluated NGS in rectal swabs of 50 patients before prostate biopsy. Multiple 
species were detected in these rectal swab samples with a median of 9 pathogens (range 1-16) 
[11]. In 35 of 50 (70%) cases multiple drug resistance genes were detected, and 24 (48%) of those 
were resistant to fluoroquinolones. Empiric prophylaxis was then modified from levofloxacin to 
NGS DNA-guided targeted antibiotic(s). In 17 cases, fungal species were detected, 11 of whom 
harbored multiple fungal spp. That was an indication to supplement prophylaxis with an antifungal 
agent. This strategy was associated with avoidance of serious infectious complications in all 
patients within 30 days after biopsy. 
Prostate Cancer 
Currently, it is thought that chronic inflammation secondary to prostate infection may play a role in 
the development and progression of prostate cancer [12]. 
Using NGS, Shrestha et al analyzed 135 urine samples which had been obtained post digital rectal 
examination [13]. Overall, there was no significant disparity in the variety of microbial populations 
between men with prostate cancer and men without, and no evidence of a connection between 
bacterial load, PSA levels, or the degree of inflammation seen on biopsy. Despite this, a group of 
bacteria were observed in this study which disproportionately existed in patients with cancer. 
Notably, these included Anaerococcus spp., among others. The importance of the detection of 
these species is that all of them have been suggested as organisms responsible for conditions 
such as prostatitis and UTI. 
Frugé et al looked at the dietary changes which impact the gut microbiota in overweight and obese 
men with prostate cancer [14]. Analysis of the microbiome from fecal samples revealed some 
‘unexpected correlations with several Firmicutes and Proteobacteria genera and biopsy Gleason 
sum at diagnosis’ were detected. Their work indicates that a possible ‘microbiome signature of 
aggressive prostate cancer’ exists, although further research must be done to determine the 
appearance of this signature, and whether it can be altered to govern the development and spread 
of prostate cancer in the future. 
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Cavarretta et al found that genera such as Staphylococcus spp. were more prevalent in samples of 
tumor tissue and, conversely, bacteria within the order of Lactobacillales, notably Streptococcus 
spp. were significantly less common in samples of tumor tissue [15]. This supports the notion that 
Streptococcus spp. may exist in the normal microbiome of the prostate and may be of benefit to 
health. Here, NGS was used to detect species which previously may not have been detected due 
to the lack of sensitivity of traditional cultures.  
Chronic Pelvic Pain Syndrome (CPPS) 
CPPS constitutes a large majority of ‘prostatitis’ cases and is typified by symptoms which last for at 
least 3 months within a 6-month period [16]. Urinary symptoms and sexual dysfunction in the 
absence of urinary tract bacterial infection is classical. So far, the etiology is not well understood 
and is thought to be heterogeneous. Shoskes et al analyzed DNA from fecal samples and found 
that there was a significantly less diverse population of microbes present within the guts of patients 
diagnosed with CPPS. Furthermore, there was evidence to suggest that there are lower amounts 
of several taxa of bacteria among patients with CPPS. Of particular interest is that quantities of 
organisms within the genera Prevotella are sufficiently low among patients with CPPS to potentially 
act as a biomarker and be a target for manipulation in the future as a means of treating this 
common condition [17].  
Urgency Urinary Incontinence 
Karstens et al revealed that there is a disparity in the prevalence of numerous groups of bacteria 
between patients with urgency urinary incontinence and those without. The results of this study 
also showed that there is a positive correlation between reduced microbial diversity and worsening 
symptoms associated with urgency urinary incontinence [18]. Within this context, it is also thought 
that microbiota has a role in a patient’s response to treatments such as anticholinergics i.e. female 
patients in whom there are smaller numbers of Lactobacillus may be more likely to suffer from a 
post-treatment UTI [19]. Several studies have so far demonstrated a similar picture in that a 
patient’s response to treatment may be affected by the diversity of bacteria and the abundance of 
particular groups [20,21].  
Neurogenic Bladder 
Using NGS, Fouts et al found that there are differences in the microbiome between patients with 
neurogenic bladder dysfunction and those with healthy bladder function. The results showed that 
there are higher levels of Lactobacillus and Corynebacterium in healthy bladders, and in patients 
with neurogenic bladder disorder, there is a tendency for higher levels of Escherichia, 
Enterococcus, and Klebsiella [22].  
Mouraviev et al presented at the last American Urology Association 2018 meeting the findings of 
NGS of urine samples from their cohort of 13 patients who all had positive bacterial or fungal 
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pathogens with catheter-associated UTI [23]. The median number of organisms present in each 
specimen was 3 species. The majority of patients had a high bacterial load (>107 microorganisms 
per ml). Resistance genes to different antibiotics detected were found in 9/13 samples and 6 of 
them had multidrug resistance genes. Of note, a standard culture in 3 patients failed to detect a 
dominant pathogen that was successfully detected by NGS and required a different targeted 
treatment. Fungi were detected in the samples of 2 patients. 
Limitations of NGS 
In order for NGS to become a routine form of diagnosis for infectious urological diseases, formal 
training in bioinformatics for clinical microbiologists would need to be considered, as would the 
development of secure, comprehensive databases, and the methodology of clinical reporting would 
have to be thought through clearly [24,25,26]. 
NGS remains a highly sensitive technique which is able to identify a whole bacterial and fungal 
association including normal inhabitants (commensal) of urine microbiome maintaining a 
reasonable balance and protection against aggressive pathogens [27]. Evidently, as more bacterial 
strains are detected, a clinical problem of determining which pathogen is responsible for UTI in 
every individual case will arise. It is also of crucial importance to distinguish pathogens from other 
contaminating or commensal flora that can be mistakenly treated with antibacterial therapy. How 
we can distinguish a clinically relevant pathogen from bystanders remains a challenging task of the 
whole analysis. There is a lot of work on standardization and creation of prediction algorithms need 
to be performed. So far, all microbes are reported to the physician because they provide useful 
information on the microbial community in the infection. The normal flora provides information 
about how the pathogens compare to the normal flora. For example, the community of bacteria in 
the vagina should have Lactobacillus. If Lactobacillus is present, the physician can use this 
information to compare the percentage of Lactobacillus (healthy flora) with the percentage of 
Atopobium parvulum to view the shift in the community and treat the pathogen. In addition, the 
information can be used to see the opportunistic pathogens that only play a role in disease in the 
presence of other organisms. For instance, Staph epidermidis is a commensal flora of skin, but 
once a wound breaks the barrier of the skin, then it can cause infection and should be something 
considered by the physician when deciding on the treatment regimen.  
Therefore, the quantitative and qualitative metrics to evaluate a baseline bacterial and fungal 
profile in normal individuals and UTI patients have to be introduced and validated in multi-
institutional trials to collect more robust data [28]. Assay validation will be a critical step in 
assessing performance, and it is imperative that standard operating procedures are constructed in 
order to produce accurate results [29]. Laboratories will need to provide independent verifications 
of test performance set side by side with other laboratories in order to ensure proficiency. This 
quality control reveals another impediment to the introduction of NGS technology – the need for a 
reference material and data set against which laboratories can assess their performance. At this 
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point in time, there are no such formal materials available, though they are currently in 
development. 
With regards to the reference library of genomic data, we realize that most of the data already 
present in the databases available may not be of good quality. Therefore, it is important to note 
that sequences and genomes can, and indeed have been poorly annotated, with some annotations 
being incorrect. The public available database like NCBI do suffer from poor and incorrect 
annotation, that can significantly compromise all the future developments. Since almost anyone 
can upload sequences to the database, they often only classify the sequence reads down to the 
taxonomy that the researcher decides, so there will be a lot of reads classified as thermal vent 
bacteria instead of the genus and species. In addition, some researchers will upload sequences 
that initially didn’t match any sequence in their subset of research, but they fail to check the 
sequences against the entire database, so they falsely call the sequence novel and provide it with 
a new name. Those are just a few of the problems that public available databases face. This is not 
inconsequential, as identification of responsible pathogens heavily relies on the accuracy of such a 
database and, as such, it is crucial that only sequences with a known origin are incorporated into 
these databases. For example, in our opinion, the database at MicroGen DX, one of the first NGS 
companies in the U.S.A, is heavily curated before being used for patient testing. For sequences to 
be entered into this database, they must go through several stages of quality verification. First, the 
sequences must cover genes of interest. Then, the sequences must be annotated in the proper 
format. If the annotation is incomplete, then they will not be incorporated for verification. Next, the 
sequences will be tested for accuracy by verifying that the sequences are attributed to the correct 
species. Any new sequence such as the ones called novel but match a current strain (i.e. 
incorrectly annotated), will be found during the accuracy check and incorporated under the proper 
name. The sequences are then run against a test set of species that have been sequenced in 
house from ATCC standards to ensure that the proper identification of these known positives has 
not been skewed. Lastly, any taxonomy changes to previous or current species are updated in the 
database. This curation occurs every 6 months. Such strict rules and standards should be 
approved and implemented by official regulatory organizations and institutions responsible for 
future implementation of metagenomics. 
As with most novel technologies, start-up costs of NGS platforms are likely to be substantial, but 
maintenance costs and the labor expenses of a well-trained technologist would also need to be 
accounted for. Despite these charges, NGS still runs at a significantly lower cost per base than 
Sanger sequencing [30]. With that said, NGS is relatively expensive when compared to technology 
such as matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF 
MS) [3]. MALDI-TOF is an interesting competitor for rapid microbial identification, but it also suffers 
drawbacks. To use MALDI-TOF, the bacteria and fungi must be cultured in order to obtain intact 
organisms and remove the human host cells. It also requires one microbe to be analyzed at once 
in order to see the specific separation related to one microbe rather than a mixture of microbes. 
Since the species have to be cultured/grown first, any species that cannot be grown or has a lot of 
difficulty growing will either be missed or delay the identification. In addition, the cells must be 
intact, so the specimen’s age and storage conditions will limit its utility. MALDI-TOF compares the 
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microbial characteristics to a database and anything that is not added or poorly annotated to the 
database will not be identified or will be identified incorrectly. This is particularly problematic for 
anaerobes and fungi which are poorly characterized in most MALDI-TOF commercially available 
databases. MALDI-TOF also have trouble with low bacterial load specimens due to the low level of 
intact organisms present. They combat this by using culture as a way to multiply the organisms, 
but culture takes time and not all species can be easily grown. As we mentioned above, NGS 
takes 3-5 days to complete the entire process from extraction to data analysis; however, if you 
include the growth time to the data analysis time for MALDI-TOF, the sample to answer time is not 
very different especially in difficult-to-identify species. 
The question of how to manage and store the copious amount of data produced is a crucial one; 
the sheer quantity of raw data involved renders its long-term storage troublesome [3]. Data can be 
stored in files that are specific to the NGS platform, but this is complicated due to the heterogeneity 
of the formats available. One way of circumventing this problem would be to use cloud-based 
storage systems, standardizing the format of the data produced by differing NGS platforms. 
However, laboratories would have to be extremely diligent, ensuring that the appropriate controls 
are in place to maintain patient confidentiality.  
Conclusion 
Until recently, the human urinary tract was believed to be a sterile region of the body when in good 
health. With the use of NGS, there is now a great deal of evidence to the contrary. The urinary 
tract possesses a microbiome and, with this new technology now available, it is possible to explore 
its role in pathology and, conversely, the impact of disease on the microbiome itself. 
Prior to the development of NGS, the main method of studying microbial communities involved 
attempting to culture the organisms that may exist within a sample. With the knowledge that the 
microbiome is an important piece of the urology puzzle, we have to be mindful of the limitations of 
cultures, and how they regularly have the effect of overlooking infections which may very well be 
crucial. 
Although NGS is at an early stage of its development, its ability to quickly detect and identify the 
entire spectrum of microbes present within a sample with accuracy, and its capacity to predict 
phenotypic resistance patterns via genomic data proves its superiority to the slower, traditional 
methods of culture and sensitivity. However, at this point in time, there are still limitations in 
precisely defining leading pathogen(s) which can contribute to the development of UTI and 
sufficiently distinguish them from other contaminating or commensal strains. The implementation of 
NGS in clinical laboratories will certainly demand a great deal of careful thought to ensure patient 
confidentiality while simultaneously storing data in a manner which will optimize public benefit. 
The further evolution of NGS will be one towards truly individualized patient care, allowing pre-
emptive diagnoses in the asymptomatic population, and predictions to be made about a patient’s 
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likelihood of developing severe UTI and design an actionable and targeted antibiotic stewardship 
based on a patient’s microbiome and their pharmacogenetics. 
With a lower cost per base than competing technologies, combined with its potential for revealing 
the intricacies of the relationship between microbiota and the human body, NGS appears to be the 
future of diagnosis, prevention, and precision treatment of a number of urological conditions. 
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